Sotrovimab: Neutralizing Antibody to Combat COVID-19

Sotrovimab is a new therapeutic agent to attenuate COVID-19. It is considered a welcome pharmaceutical preparation in light of SARS-CoV-2 variants, such as Omicron. Some other monoclonal antibody medications have low effectiveness at blocking Omicron’s SARS-CoV-2 cell access. Sotrovimab fills an important therapeutic niche for victims of Omicron infection and is indicated for anyone with medical contraindications to vaccines, persons with serious comorbidities, and immunocompromised persons with suboptimal response to vaccines, and it may be especially helpful with the emergence of variant viral infections that evade vaccineor illness-derived immunity.[1, 2] Sotrovimab reduces the risk of disease progression among high-risk patients with mild-tomoderate COVID-19.[3] Sotrovimab may also reduce the percentage of patients who require oxygen.[4] It seems that sotrovimab is a better choice for dealing with severe or non-severe COVID-19 patients.[5] Hopefully, it will provide high efficacy to patients with early COVID-19, minimizing hospitalizations, morbidity, mortality, and/or healthcare system overload.